By Phil Collis, VP Scientific Affairs and Professor Gordon McVie, Oncology Advisor at Inveresk
Phil Collis has been Vice President of Scientific Affairs, Global Clinical at Inveresk Research in North Carolina since October 2003. He is principally responsible for international strategic client liaison and consulting on clinical development plans, regulatory strategy and feasibility analysis. Prior to this, he was Director and then Vice President of International Operations for PharmaResearch Corporation in the UK. He has also worked as a Principal Clinical Research Scientist, Senior Clinical Research Scientist and Clinical Research Scientist for Glaxo Wellcome Research and Development. Phil gained his PhD in Molecular Genetics and also studied for his BSc (Hons) in Biochemistry at the University of London. He is an Associate of the Royal College of Science and a Member of the Institute for Clinical Research (ICR), the International AIDS Society, British HIV Association and the Drug Industry Association (DIA).
Professor Gordon McVie MD, FRCP, FRCPS, FRCSE, FMedSci, DSc(Hon) is widely regarded as a leading international authority in the research and treatment of cancer. He is currently Director of Cancer Intelligence, an advisory body to biotechnology and pharmaceutical companies, investors, the media and cancer patients. He is a Visiting Professor at Glasgow University, Scotland; honorary Consultant in Medical Oncology at the Welsh Cancer Institute, Cardiff; Clinical Research Director at the European Institute of Oncology, Milan; and Oncology Advisor to Inveresk. Previously Professor McVie was Chief Executive of the Cancer Research Campaign (CRC). He has authored almost 300 peer-reviewed articles, contributed to over 35 books and is currently European Editor for the US Journal of the National Cancer Institute.
|
|
